Article Text

Download PDFPDF

Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism
  1. M. Clemente, DVM1,
  2. P. J. De Andrés, DVM1,
  3. C. Arenas, DVM2,
  4. C. Melián, DVM, PhD3,
  5. M. Morales, DVM, PhD4 and
  6. M. D. Pérez-Alenza, DVM, PhD1
  1. 1 Veterinary Teaching Hospital, Veterinary School, Complutense University, 28040 Madrid, Spain
  2. 2 Veterinary School, Alfonso X El Sabio University, 28691 Madrid, Spain
  3. 3 Clínica Veterinaria Atlántico, Pi y Margall 42, 35006 Las Palmas de Gran Canaria, Spain
  4. 4 Veterinary School, Las Palmas de Gran Canaria University, 35416 Arucas, Gran Canaria, Spain


Forty-six dogs with pituitary-dependent hyperadrenocorticism were treated with mitotane by the non-selective adrenocorticolysis protocol and 40 were treated twice a day with trilostane. The treatment groups were compared by chi-squared tests, and survival data were analysed using Kaplan-Meier survival plots and a Cox proportional hazard method. The non-selective adrenocorticolysis protocol was very effective (89 per cent), its toxicity was moderate (24 per cent) and there were fewer recurrences (29 per cent) than reported with the classical selective adrenocorticolysis protocol (58 per cent). In a multivariate model, age and bodyweight at diagnosis were significantly negatively correlated with survival time. The median survival time of the dogs treated with trilostane twice a day (900 days) was longer (P=0·05) than that of the dogs treated with mitotane (720 days).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.